|
Variable
|
Median
|
Range
|
|---|
|
Age at diagnosis (years)
|
57
|
36–73
|
|
Body mass index
|
26.54
|
20.04–39.15
|
|
PSA at diagnosis (ng/ml)
|
5.99
|
1.29–38
|
|
Variable
|
Frequency
|
%
|
|---|
|
Race
|
|
African American
|
17
|
8.5
|
|
Asian
|
2
|
1
|
|
Caucasian
|
173
|
86.5
|
|
Other
|
8
|
4
|
|
Family history of prostate cancer
|
|
No
|
112
|
56
|
|
Yes
|
73
|
36.5
|
|
TNM stage
|
|
Local
|
132
|
66
|
|
Advanced
|
68
|
34
|
|
Gleason score
|
|
6
|
110
|
55
|
|
7 (3 + 4)
|
56
|
28
|
|
7 (4 + 3)
|
11
|
5.5
|
|
8
|
14
|
7
|
|
9–10
|
9
|
4.5
|
|
Extraprostatic extension
|
|
No
|
136
|
68
|
|
Yes
|
63
|
31.5
|
|
Lymph node metastases
|
|
No
|
195
|
97.5
|
|
Yes
|
3
|
1.5
|
|
Distant metastasis
|
|
No
|
165
|
82.5
|
|
Yes
|
6
|
3
|
|
Adjuvant therapya
|
|
None
|
169
|
84.5
|
|
Adjuvant radiation only
|
2
|
1
|
|
Chemotherapya
|
|
No
|
168
|
84
|
|
Yes
|
3
|
1.5
|
|
Radiation therapya
|
|
No
|
160
|
80
|
|
Yes
|
11
|
5.5
|
|
Hormonal therapya
|
|
No
|
160
|
80
|
|
Yes
|
12
|
6
|
|
Surgical margin status
|
|
Negative
|
169
|
84.5
|
|
Positive
|
31
|
15.5
|
|
Seminal vesicle involvement
|
|
No
|
186
|
93
|
|
Yes
|
14
|
7
|
- Numbers do not always add up to 200 (or 100%) in some categories because of cases with missing data
- aAll treatment modalities were applied postoperatively
